Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,153 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) insider Oxana Beskrovnaya sold 2,153 shares of Dyne Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total transaction of $24,501.14. Following the completion of the transaction, the insider now directly owns 195,840 shares in the company, valued at approximately $2,228,659.20. The trade was a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Oxana Beskrovnaya also recently made the following trade(s):

  • On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10.

Dyne Therapeutics Stock Up 1.4 %

Shares of Dyne Therapeutics stock opened at $12.05 on Friday. The stock’s 50-day simple moving average is $14.83 and its 200-day simple moving average is $25.63. Dyne Therapeutics, Inc. has a 52 week low of $11.18 and a 52 week high of $47.45. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -3.38 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DYN. Chardan Capital reiterated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, February 28th. Robert W. Baird initiated coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.85.

View Our Latest Report on Dyne Therapeutics

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $34,000. Point72 DIFC Ltd purchased a new position in Dyne Therapeutics during the 3rd quarter valued at $36,000. US Bancorp DE increased its stake in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. GF Fund Management CO. LTD. purchased a new position in Dyne Therapeutics in the 4th quarter worth about $50,000. Finally, KBC Group NV grew its stake in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Further Reading

Insider Buying and Selling by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.